Medtronic secured FDA clearance for its MiniMed Fit, a tubeless insulin pump offering up to seven-day wear and 50% more insulin capacity. Meanwhile, the broader market saw quarterly financial results from major retailers including The Home Depot, Target, and Lowe's. Additionally, Novo Nordisk launched its Novocare support program for Wegovy patients, providing home delivery and digital tracking tools.
The FDA cleared MiniMed Fit, described as the world's first tubeless insulin pump with up to seven-day wear and zero interruptions, offering up to twice the wear time of other tubeless options and 50% more insulin capacity. A regulatory clearance is a concrete approval milestone for the diabetes device franchise, though the release gives no revenue or launch-scale figures to size the benefit.
- ▲ FDA clearance of MiniMed Fit tubeless insulin pump
- ▲ Product claims of up to seven-day wear and 50% more insulin capacity
- ▼ No sales figures, pricing or launch timeline disclosed
- ▼ Clearance is announced via a product press release without financial detail